BACKGROUND: Prognostic metabolic imaging indices are needed for risk stratification for patients with locally advanced oropharyngeal cancer. METHODS: We retrospectively examined pretreatment and midtreatment fluorodeoxyglucose-positron emission tomography (FDG-PET) parameters in patients with locally advanced oropharyngeal cancer who were treated with definitive chemoradiation. RESULTS: A total of 74 patients were evaluated. Pretreatment metabolic tumor volume (MTV) using threshold of 50% standardized uptake value (SUV) maximum (MTV50% ) was associated with progression-free survival (PFS; p = .003; hazard ratio [HR] = 1.57 per 10 cc; 95% confidence interval [CI] = 1.17-2.11) and overall survival (OS; p = .01; HR = 1.36 per 10 cc; 95% CI = 1.07-1.74). Midtreatment MTV using a threshold of SUV 2.0 (MTV2.0 ) was associated with PFS (p < .001; HR = 1.24 per 10 cc; 95% CI = 1.10-1.39) and OS (p = .009; HR = 1.21 per 10 cc; 95% CI = 1.05-1.39). Nodal total lesion glycolysis (TLG) velocity >5% decrease/week was associated with improved PFS (p = .04; HR = 0.37; 95% CI = 0.15-0.95). CONCLUSION: Metabolic response during chemoradiation is associated with survival in locally advanced oropharyngeal cancer and may aid with risk-adapting treatment.
BACKGROUND: Prognostic metabolic imaging indices are needed for risk stratification for patients with locally advanced oropharyngeal cancer. METHODS: We retrospectively examined pretreatment and midtreatment fluorodeoxyglucose-positron emission tomography (FDG-PET) parameters in patients with locally advanced oropharyngeal cancer who were treated with definitive chemoradiation. RESULTS: A total of 74 patients were evaluated. Pretreatment metabolic tumor volume (MTV) using threshold of 50% standardized uptake value (SUV) maximum (MTV50% ) was associated with progression-free survival (PFS; p = .003; hazard ratio [HR] = 1.57 per 10 cc; 95% confidence interval [CI] = 1.17-2.11) and overall survival (OS; p = .01; HR = 1.36 per 10 cc; 95% CI = 1.07-1.74). Midtreatment MTV using a threshold of SUV 2.0 (MTV2.0 ) was associated with PFS (p < .001; HR = 1.24 per 10 cc; 95% CI = 1.10-1.39) and OS (p = .009; HR = 1.21 per 10 cc; 95% CI = 1.05-1.39). Nodal total lesion glycolysis (TLG) velocity >5% decrease/week was associated with improved PFS (p = .04; HR = 0.37; 95% CI = 0.15-0.95). CONCLUSION: Metabolic response during chemoradiation is associated with survival in locally advanced oropharyngeal cancer and may aid with risk-adapting treatment.
Authors: Thong Chotchutipan; Benjamin S Rosen; Peter G Hawkins; Jae Y Lee; Anjali L Saripalli; Dharmesh Thakkar; Avraham Eisbruch; Issam El Naqa; Michelle L Mierzwa Journal: Head Neck Date: 2018-12-12 Impact factor: 3.147
Authors: Yue Cao; Catherine T Haring; Michelle Mierzwa; J Chad Brenner; Collin Brummel; Chandan Bhambhani; Madhava Aryal; Choonik Lee; Molly Heft Neal; Apurva Bhangale; Wenjin Gu; Keith Casper; Kelly Malloy; Yilun Sun; Andrew Shuman; Mark E Prince; Matthew E Spector; Steven Chinn; Jennifer Shah; Caitlin Schonewolf; Jonathan B McHugh; Ryan E Mills; Muneesh Tewari; Francis P Worden; Paul L Swiecicki Journal: Clin Cancer Res Date: 2021-10-26 Impact factor: 13.801
Authors: Kyle J Lafata; Yushi Chang; Chunhao Wang; Yvonne M Mowery; Irina Vergalasova; Donna Niedzwiecki; David S Yoo; Jian-Guo Liu; David M Brizel; Fang-Fang Yin Journal: Med Phys Date: 2021-06-02 Impact factor: 4.506
Authors: Yue Cao; Madhava Aryal; Pin Li; Choonik Lee; Matthew Schipper; Peter G Hawkins; Christina Chapman; Dawn Owen; Aleksandar F Dragovic; Paul Swiecicki; Keith Casper; Francis Worden; Theodore S Lawrence; Avraham Eisbruch; Michelle Mierzwa Journal: Front Oncol Date: 2019-11-14 Impact factor: 6.244
Authors: Lauren J Beesley; Andrew G Shuman; Michelle L Mierzwa; Emily L Bellile; Benjamin S Rosen; Keith A Casper; Mohannad Ibrahim; Sarah M Dermody; Gregory T Wolf; Steven B Chinn; Matthew E Spector; Robert J Baatenburg de Jong; Emilie A C Dronkers; Jeremy M G Taylor Journal: JAMA Netw Open Date: 2021-08-02